StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
7516.TWO$9.30+0.00%
Fair $9.30+0.0%

7516.TWO

Sea Mild Biotechnology Co., Ltd.

Consumer Defensive / Household & Personal ProductsTaipei Exchange

$9.30

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $9.30Fund rank 25/100 · Data gapFallback financials|
SA 34/D
F-Score: 2/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 32% · confianza 21%

FCF escenarios

weak_data · normalized FCF $7.6M · quality 38.0/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 28/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

34/100

D

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific biotech pipeline model required: targets are disabled until product, probability, peak-sales and cash-runway data exists.
Thesis & Journal · 7516.TWOLocal privado en este navegador · Sea Mild Biotechnology Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$180M

P/E

20.2x

↑

EV/EBITDA

6.2x

↓

ROE

8.0%

↑

Gross Margin

26.1%

↓

Debt/Equity

1.11

↑
52-Week Range$9
$9$15

TradingView lightweight chart

7516.TWO price, volumen y niveles de valoración

Último $9.300Periodo -77.3%
Fair value: $9.300

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+19.1%

FCF CAGR

—

FCF margin

-2.2%

FCF / Net income

-0.84x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $341.9M · net income $8.8M · FCF $-7.4M

2022-FY → 2025-FY

Gross margin

26.1%+8.2% pts

Operating margin

2.1%+8.0% pts

Net margin

2.6%+13.1% pts

FCF margin

-2.2%-7.8% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$341.9M$341.9M$318.8M$257.0M$202.6M
Net Income$8.8M$8.8M$32.0M$6.2M$-21.4M
EBITDA$34.7M$34.7M$53.2M$21.6M$-5.6M
EPS——1.660.32-1.11
Gross Margin26.1%26.1%28.6%21.9%17.8%
Operating Margin2.1%2.1%7.0%1.9%-5.9%
Net Margin2.6%2.6%10.0%2.4%-10.6%
Balance Sheet
Debt/Equity1.111.110.680.780.47
Current Ratio1.451.45———
Cash Flow
Free Cash Flow$-7.4M$-7.4M$23.0M$7.6M$11.4M
Returns
ROE8.0%8.0%31.2%8.8%-33.2%
Valuation
P/E20.2220.227.5936.25—
EV/EBITDA6.156.154.3310.77—
P/B1.621.622.383.181.14
Growth & Yield
Revenue Growth7.2%7.2%24.0%26.8%—
EPS Growth——418.7%128.8%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -9.3%

Total return

-9.3%

Start / end P/E

n/dx → n/dx

EPS bridge

1.66 → n/d

Residual

-9.3%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-9.3%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.